GlaxoSmithKline plc (GSK) Insider Buys £124.32 in Stock

GlaxoSmithKline plc (LON:GSK) insider Simon Dingemans purchased 8 shares of the firm’s stock in a transaction that occurred on Monday, February 11th. The stock was bought at an average price of GBX 1,554 ($20.31) per share, for a total transaction of £124.32 ($162.45).

Shares of LON:GSK opened at GBX 1,547 ($20.21) on Thursday. GlaxoSmithKline plc has a 12-month low of GBX 1,235.20 ($16.14) and a 12-month high of GBX 1,724.50 ($22.53).

The firm also recently announced a dividend, which will be paid on Thursday, April 11th. Shareholders of record on Thursday, February 21st will be given a dividend of GBX 23 ($0.30) per share. This represents a dividend yield of 1.49%. The ex-dividend date is Thursday, February 21st. This is a positive change from GlaxoSmithKline’s previous dividend of $19.00.

A number of brokerages recently commented on GSK. Deutsche Bank set a GBX 1,520 ($19.86) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Tuesday. Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline in a research note on Friday, February 8th. Kepler Capital Markets set a GBX 1,440 ($18.82) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, February 7th. Credit Suisse Group set a GBX 1,600 ($20.91) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, February 7th. Finally, HSBC upped their price target on shares of GlaxoSmithKline from GBX 1,820 ($23.78) to GBX 1,860 ($24.30) and gave the company a “buy” rating in a research note on Thursday, February 7th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of GBX 1,520.93 ($19.87).

TRADEMARK VIOLATION WARNING: This piece of content was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2019/02/14/glaxosmithkline-plc-gsk-insider-buys-124-32-in-stock.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: What do investors mean by earnings per share?

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply